GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cronos Group Inc (NAS:CRON) » Definitions » Total Liabilities

Cronos Group (Cronos Group) Total Liabilities : $35.76 Mil (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Cronos Group Total Liabilities?

Cronos Group's Total Liabilities for the quarter that ended in Mar. 2024 was $35.76 Mil.

Cronos Group's quarterly Total Liabilities increased from Sep. 2023 ($33.35 Mil) to Dec. 2023 ($43.96 Mil) but then declined from Dec. 2023 ($43.96 Mil) to Mar. 2024 ($35.76 Mil).

Cronos Group's annual Total Liabilities increased from Dec. 2021 ($63.46 Mil) to Dec. 2022 ($72.05 Mil) but then declined from Dec. 2022 ($72.05 Mil) to Dec. 2023 ($43.96 Mil).


Cronos Group Total Liabilities Historical Data

The historical data trend for Cronos Group's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cronos Group Total Liabilities Chart

Cronos Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 341.41 217.51 63.46 72.05 43.96

Cronos Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.18 31.67 33.35 43.96 35.76

Cronos Group Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Cronos Group's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=41.399+(1.559+1.003
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=43.96

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=1140.085-1096.124
=43.96

Cronos Group's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=33.419+(1.305+1.033
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=35.76

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=1108.535-1072.778
=35.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cronos Group Total Liabilities Related Terms

Thank you for viewing the detailed overview of Cronos Group's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Cronos Group (Cronos Group) Business Description

Traded in Other Exchanges
Address
111 Peter Street, Suite 300, Toronto, ON, CAN, M5V 2H1
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S. the company has an option to acquire 10.5% of U.S. multistate operator PharmaCann upon easing of federal prohibition.
Executives
Kamran Khan director 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Elizabeth Seegar director 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Dominik Meier director 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Jason Marc Adler director 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2G9
Mcginness James Andrew Iii officer: VP, Controller C/O MARKETWISE, 1125 N. CHARLES STREET, BALTIMORE MD 21201
Maple Holdco (bermuda) Ltd. 10 percent owner C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Maple Acquireco (canada) Ulc 10 percent owner C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Altria Summit Llc 10 percent owner C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Altria Group, Inc. 10 percent owner 6601 WEST BROAD STREET, RICHMOND VA 23230
James Holm officer: Chief Financial Officer 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Arye Weigensberg officer: See Remarks 111 PETER STREET, SUITE 300, TORONTO A6 MV5 2H1
Doucet Terrence Gregory Joseph officer: See Remarks 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
John Griese officer: See Remarks 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Ran Gorelik officer: General Manager (Israel) 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Robert L Madore officer: Chief Financial Officer C/O RALPH LAUREN CORPORATION, 650 MADISON AVENUE, NEW YORK NY 10022